Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments

Equality Impact Assessment (Guidance development) (PDF 143 KB)

Final draft guidance

Final draft guidance (PDF 235 KB)

Committee papers (PDF 5.34 MB)

Public committee slides (PDF 1.03 MB)

Final draft guidance : Equality Impact Assessment (PDF 143 KB)

Committee meeting

Supporting documentation Register of Interests (PDF 198 KB)

Final scope (PDF 159 KB)

Final stakeholder list (PDF 163 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 203 KB)

Equality impact assessment (Scoping) (PDF 120 KB)

Supporting documentation Topic Selection HST checklist (PDF 164 KB)

Draft matrix post referral (PDF 165 KB)

Draft scope post referral (PDF 174 KB)